Literature DB >> 7819066

RNA transcripts of the beta-thalassaemia allele IVS-2-654 C-->T: a small amount of normally processed beta-globin mRNA is still produced from the mutant gene.

S Z Huang1, F Y Zeng, Z R Ren, Z H Lu, G P Rodgers, A N Schechter, Y T Zeng.   

Abstract

IVS-2-654 C-->T is a common Chinese beta-thalassaemia mutation. Previous studies report that this mutation resulted in the formation of an abnormally spliced mRNA and the absence of detectable normal beta-globin mRNA, hence the mutation was considered to cause beta o-thalassaemia. We recently used the method of PCR amplified cDNA copies of circulating erythroid cell mRNA to analyse the mutant gene transcripts and found that this IVS-2-654 mutation does not abolish normal RNA processing entirely, but that a significant amount (over 15%) of normally processed beta-globin mRNA is produced. Microglobin chain biosynthetic analysis using the HPLC method showed that beta-globin chain was also present in the blood of patients with IVS-2-654 C-->T mutation. Accordingly, this mutant allele leads to a beta (+)-thalassaemia. Further, the methodology described in this paper provides a new approach towards the detection of RNA transcripts of beta-thalassaemia alleles as well as the study of gene expression in beta-thalassaemia and other genetic diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7819066     DOI: 10.1111/j.1365-2141.1994.tb05071.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Correction of β654-thalassaemia mice using direct intravenous injection of siRNA and antisense RNA vectors.

Authors:  Shu-Yang Xie; Wei Li; Zhao-Rui Ren; Shu-Zhen Huang; Fanyi Zeng; Yi-Tao Zeng
Journal:  Int J Hematol       Date:  2011-03-04       Impact factor: 2.490

2.  Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients.

Authors:  G Lacerra; H Sierakowska; C Carestia; S Fucharoen; J Summerton; D Weller; R Kole
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

3.  Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.

Authors:  H Sierakowska; M J Sambade; S Agrawal; R Kole
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

4.  Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing.

Authors:  Haokun Zhang; Ruilin Sun; Jian Fei; Hongyan Chen; Daru Lu
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

5.  Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia.

Authors:  Guanheng Yang; Wansheng Shi; Xingyin Hu; Jingzhi Zhang; Zhijuan Gong; Xinbing Guo; Zhaorui Ren; Fanyi Zeng
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

6.  Treatment of β654 -thalassaemia by TALENs in a mouse model.

Authors:  Yudan Fang; Yan Cheng; Dan Lu; Xiuli Gong; Guanheng Yang; Zhijuan Gong; Yiwen Zhu; Xiao Sang; Shuyue Fan; Jingzhi Zhang; Fanyi Zeng
Journal:  Cell Prolif       Date:  2018-08-02       Impact factor: 6.831

Review 7.  U7 snRNA: A tool for gene therapy.

Authors:  Ankur Gadgil; Katarzyna Dorota Raczyńska
Journal:  J Gene Med       Date:  2021-02-23       Impact factor: 4.565

8.  Enhancement of β-Globin Gene Expression in Thalassemic IVS2-654 Induced Pluripotent Stem Cell-Derived Erythroid Cells by Modified U7 snRNA.

Authors:  Phetcharat Phanthong; Suparerk Borwornpinyo; Narisorn Kitiyanant; Natee Jearawiriyapaisarn; Lalana Nuntakarn; Jirawat Saetan; Tiwaporn Nualkaew; Khanit Sa-Ngiamsuntorn; Usanarat Anurathapan; Andras Dinnyes; Yindee Kitiyanant; Suradej Hongeng
Journal:  Stem Cells Transl Med       Date:  2017-02-18       Impact factor: 6.940

9.  β‑thalassemia caused by compound heterozygous mutations and cured by bone marrow transplantation: A case report.

Authors:  Liusong Wu; Zhiyu Peng; Sen Lu; Mei Tan; Ying Rong; Runmei Tian; Yuhang Yang; Yan Chen; Jindong Chen
Journal:  Mol Med Rep       Date:  2017-09-12       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.